Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GH Research (GHRS)
NASDAQ:GHRS
Holding GHRS?
Track your performance easily
GHRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.05 - $14.99
Previous Close$7.99
Volume45.21K
Average Volume (3M)34.82K
Market Cap
$405.82M
Enterprise Value$310.73M
Total Cash (Recent Filing)$105.94M
Total Debt (Recent Filing)$974.00K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 07, 2024EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding52,028,145
10 Day Avg. Volume31,339
30 Day Avg. Volume34,819
Standard Deviation0.18
R-Squared0.06
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.90
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.70K
Forecast
1Y Price Target
$36.67Price Target Upside370.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
GH Research News
PremiumCompany Announcements
GH Research Engages Investors at Healthcare Conference
PremiumCompany Announcements
GH Research to Engage at Global Investment Conference
PremiumCompany Announcements
GH Research to Connect at Global Healthcare Conference
PremiumCompany Announcements
GH Research Reports Increased Operational LossBulls Say, Bears Say
Bulls Say
Drug Development ProgressGH001 is progressing in multiple Phase 2 trials with near-term readouts, expected to de-risk the lead program.
Financial HealthGH Research has sufficient cash reserves, which management believes are enough to fund operations.
Intellectual PropertyGH boasts robust intellectual property positioning and its GH001 treatment has immediate effect compared to competitors.
Bears Say
Clinical Trial ConcernsGH needs to further assess the impact of measures implemented to improve recruitment in the Phase 2 trial.
Clinical Trial DelaysGH needs to assess the impact of measures implemented to improve recruitment for the Phase 2 trial in bipolar II disorder before providing an updated timeline.
Regulatory ChallengesThe clinical hold on the IND application for GH001 is a setback for transitioning to a novel aerosol device.
---
Ownership Overview
0.00%
Insiders
4.29% Mutual Funds
49.53% Other Institutional Investors
46.18% Public Companies and
Individual Investors
GHRS FAQ
What was GH Research’s price range in the past 12 months?
GH Research lowest stock price was $5.05 and its highest was $14.99 in the past 12 months.
What is GH Research’s market cap?
Currently, no data Available
When is GH Research’s upcoming earnings report date?
GH Research’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were GH Research’s earnings last quarter?
GH Research released its earnings results on Sep 03, 2024. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.22 by $0.02.
Is GH Research overvalued?
According to Wall Street analysts GH Research’s price is currently Undervalued.
Does GH Research pay dividends?
GH Research does not currently pay dividends.
What is GH Research’s EPS estimate?
GH Research’s EPS estimate is -$0.25.
How many shares outstanding does GH Research have?
GH Research has 52,028,145 shares outstanding.
What happened to GH Research’s price movement after its last earnings report?
GH Research reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.22. Following the earnings report the stock price went down -6.571%.
Which hedge fund is a major shareholder of GH Research?
Among the largest hedge funds holding GH Research’s share is RA Capital Management. It holds GH Research’s shares valued at 77M.
---
GH Research Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.67 (370.13% Upside)
$36.67 (370.13% Upside)
Blogger Sentiment
Bullish
GHRS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 350.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.90%
12-Months-Change
Fundamentals
Return on Equity
-16.20%
Trailing 12-Months
Asset Growth
-13.86%
Trailing 12-Months
Company Description
GH Research
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
---
GHRS Stock 12 Month Forecast
Average Price Target
$36.67
▲(370.13% Upside)
Technical Analysis
Best Analysts Covering GHRS
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-5.40%
reiterated a buy rating 15 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -5.40% per trade.
---